How is the development of generic EXPAREL by Pacira Biosciences progressing?
As of recent information, Pacira Biosciences is the developer of EXPAREL, an injectable liposomal bupivacaine for extended local pain control [1]. The company has been involved in litigation regarding its patents for EXPAREL, with challengers aiming to bring generic versions to market [2].
What are the key patents protecting EXPAREL?
EXPAREL is protected by a portfolio of patents, with U.S. Patent No. 9,700,618 being a significant one [2]. This patent, covering methods of manufacturing EXPAREL, has been a focal point in patent litigation proceedings.
Why are companies challenging EXPAREL patents?
Companies seeking to market generic versions of EXPAREL are challenging its patents primarily to clear the path for their products. These challenges often involve arguing that the patents are invalid or should not be infringed upon by the generic product [2]. For example, a litigation involving Teva Pharmaceuticals questioned the validity of the '618 patent [2].
When does EXPAREL patent exclusivity expire?
While specific expiration dates can be complex due to patent term extensions and litigation outcomes, challenges to patents like U.S. Patent No. 9,700,618 suggest that exclusivity may be contested before its natural expiration [2]. Information on specific patent expirations and potential generic entry dates can be tracked on sites like DrugPatentWatch.com [3].
What are the implications of generic EXPAREL for pain management?
The introduction of generic EXPAREL could potentially lead to increased accessibility and lower costs for patients requiring extended local anesthesia for post-surgical pain [1, 3]. This could expand its use across various surgical procedures.
How does EXPAREL work for pain relief?
EXPAREL is a non-opioid local anesthetic that utilizes DepoFoam drug delivery technology to provide pain relief for up to 72 hours after a single administration [1]. It releases bupivacaine slowly over time, targeting the site of surgical incision or manipulation.
What are the risks or side effects associated with EXPAREL?
Common side effects reported for EXPAREL include nausea, constipation, headache, fever, fatigue, and vomiting [1]. Serious side effects can include cardiac arrest, cardiac arrhythmias, and central nervous system effects.
What is the current litigation status regarding EXPAREL generics?
Pacira Biosciences has engaged in legal battles to defend its patents. These litigations often involve Paragraph IV certifications filed by generic companies, asserting that Pacira's patents are invalid, unenforceable, or will not be infringed by the generic drug [2]. The outcomes of these legal challenges are crucial for determining when generic versions can enter the market.
Who are the potential competitors for EXPAREL?
Companies that have filed or are expected to file Abbreviated New Drug Applications (ANDAs) for generic versions of EXPAREL are potential competitors. Teva Pharmaceuticals has been identified as one such entity involved in patent disputes related to EXPAREL [2].
Where can I find more information on EXPAREL patents and generics?
Resources like DrugPatentWatch.com provide detailed information on drug patents, exclusivity periods, and the status of generic drug development, including for products like EXPAREL [3].
Sources:
1. https://www.exparel.com/
2. https://www.law360.com/articles/1738569/pacira-beats-back-challenge-to-exparel-manufacturing-patent
3. https://drugpatentwatch.com/